Fig. 5From: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinomaKaplan–Meier survival curves of OS% in 8 patients with Nasopharyngeal Carcinoma treated with immunotherapy and stereotactic ablative radiotherapyBack to article page